



PRESS RELEASE

Peptomyc Appoints Stephan Braun, MD, PhD, as Chief Medical Officer

Barcelona, Spain – [Date] – Peptomyc, a clinical-stage biotechnology company developing OMO-103, a first-in-class direct MYC inhibitor, today announced the appointment of Stephan Braun, MD, PhD, as Chief Medical Officer.

Dr. Braun brings extensive experience in oncology drug development, clinical strategy, and biotechnology leadership. He will lead Peptomyc's medical and clinical development strategy as the company advances OMO-103 and prepares for its next phase of development and strategic partnering.

"Stephan joins Peptomyc at an important moment," said Jesús Martín García, Chief Executive Officer of Peptomyc. "OMO-103 has generated a differentiated clinical and translational dataset, and we are now focused on defining the most compelling path forward for the program. Stephan's clinical development expertise, strategic judgment, and experience in oncology biotechnology will be highly valuable as we move into this next phase."

Dr. Braun has held senior medical and clinical development roles in oncology-focused biotechnology companies, including CureTeq, Basilea, Ipsen, Parexel, Symphogen, and most recently as Chief Medical Officer of ImCheck Therapeutics. Earlier in his industry career, he served in international leadership roles at Amgen, supporting development, approval and medical affairs activities of Aranesp®, Xgeva®, and Vectibix®. During his academic tenure, Dr. Braun was a professor at the Department of Obstetrics and Gynecology at the medical universities in Munich and Innsbruck from 1994 until 2008, building and leading the Breast Cancer Center and Gynecologic Oncology Center teams. He has authored 35 peer-reviewed publications in translational research and oncology, and served on the editorial boards of several scientific journals. In addition, he is an active member of the American Society of Clinical Oncology (ASCO), American Association for Cancer Research (AACR), American Society of Hematology (ASH), and European Society for Medical Oncology (ESMO). His experience spans clinical development strategy, regulatory interactions, translational medicine, and partnering-oriented development planning.

"I am pleased to join Peptomyc and to work with the team at this important stage," said Stephan Braun, MD, PhD. "OMO-103 is a highly differentiated approach to targeting MYC, one of the most important and historically challenging drivers of cancer. I am looking forward to contributing to the clinical strategy and to advancing the program toward its next value-defining milestones."

About Peptomyc

Peptomyc is a clinical-stage biotechnology company focused on the development of OMO-103, a direct pan-MYC inhibitor based on the Omomyc mini-protein. MYC is one of the most frequently deregulated oncogenic drivers in cancer and has long been considered difficult to target. Peptomyc is advancing OMO-103 through clinical development with the objective of establishing a new therapeutic approach for patients with MYC-driven tumors. Peptomyc was founded by Dr. Laura Soucek, one of the world's leading scientific experts on MYC, whose pioneering research on the Omomyc mini-protein established the scientific foundation for the company's approach.



Media Contact

Peptomyc S.L.
info@peptomyc.com